Jones Financial Companies Lllp Grows Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Jones Financial Companies Lllp lifted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 80.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,261 shares of the company’s stock after acquiring an additional 5,022 shares during the quarter. Jones Financial Companies Lllp’s holdings in CRISPR Therapeutics were worth $443,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of CRSP. Boston Family Office LLC raised its holdings in shares of CRISPR Therapeutics by 2.2% in the third quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock valued at $459,000 after acquiring an additional 213 shares in the last quarter. Bedell Frazier Investment Counselling LLC raised its holdings in shares of CRISPR Therapeutics by 0.8% in the 3rd quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock valued at $1,238,000 after purchasing an additional 218 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of CRISPR Therapeutics by 1.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock worth $586,000 after purchasing an additional 231 shares during the period. Sunbelt Securities Inc. lifted its position in shares of CRISPR Therapeutics by 11.3% in the 3rd quarter. Sunbelt Securities Inc. now owns 2,955 shares of the company’s stock worth $139,000 after purchasing an additional 300 shares during the period. Finally, Kestra Private Wealth Services LLC boosted its stake in shares of CRISPR Therapeutics by 1.5% during the fourth quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company’s stock valued at $812,000 after purchasing an additional 310 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Analyst Upgrades and Downgrades

CRSP has been the subject of a number of analyst reports. Stifel Nicolaus lowered their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a report on Thursday, February 13th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research note on Thursday, February 13th. Evercore ISI upgraded CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and lifted their target price for the company from $60.00 to $99.00 in a research note on Friday, February 14th. Bank of America decreased their price target on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, Truist Financial lifted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, CRISPR Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $73.11.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 18,360 shares of the business’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John Greene purchased 7,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 26th. The stock was bought at an average cost of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the acquisition, the director now directly owns 7,000 shares of the company’s stock, valued at $313,950. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $43.34 on Tuesday. CRISPR Therapeutics AG has a 12-month low of $36.52 and a 12-month high of $79.33. The firm’s 50-day moving average is $42.88 and its two-hundred day moving average is $45.71. The company has a market capitalization of $3.72 billion, a PE ratio of -9.92 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.